Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is well-positioned for market success, with a strong financial position and upcoming Phase 2 studies planned for their various treatments, including a potential $50 oral NTCP inhibitor for hepatitis D virus in the works with Gilead. With a recent increase in revenue and a focus on potential monotherapy and combination treatments for PBC and PSC, the company has the potential to see significant growth and success in the near future. Additionally, their collaboration with Gilead for their HSV program and plans for other potential treatments showcase their commitment to innovation and expansion in the pharmaceutical industry.

Bears say

Assembly Biosciences is struggling to gain recognition for the commercial potential of their oral therapy for HSV and has faced delays and strategic pivots in their HBV program. While the company has a potential new partnership that could bring in non-dilutive funding, their current financials and lack of inclusion of their HBV program in their model suggest a potential lack of confidence in their success.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.